Merck KGaA

BST:MRKC Stock Report

Market Cap: €60.1b

Merck KGaA Past Earnings Performance

Past criteria checks 2/6

Merck KGaA has been growing earnings at an average annual rate of 13.4%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 6.4% per year. Merck KGaA's return on equity is 9.5%, and it has net margins of 12.9%.

Key information

13.4%

Earnings growth rate

13.4%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate6.4%
Return on equity9.5%
Net Margin12.9%
Next Earnings Update06 Mar 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Merck KGaA makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BST:MRKC Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2420,9632,6965,7292,412
30 Jun 2420,8702,6265,7352,469
31 Mar 2420,8202,7225,7382,423
31 Dec 2320,9932,8245,7862,439
30 Sep 2321,4282,8935,9002,399
30 Jun 2322,0613,0786,0352,460
31 Mar 2322,3273,2426,0752,458
31 Dec 2222,2323,3265,9822,447
30 Sep 2221,7853,4735,9252,411
30 Jun 2220,9523,3115,7452,436
31 Mar 2220,2543,1885,5572,428
31 Dec 2119,6873,0555,4612,418
30 Sep 2119,0722,6895,3342,466
30 Jun 2118,5462,7335,2342,330
31 Mar 2117,7952,2785,2302,259
31 Dec 2017,5341,9875,3002,262
30 Sep 2017,3171,8845,4532,231
30 Jun 2016,9241,4195,5502,258
31 Mar 2016,7761,5495,6432,291
31 Dec 1916,1521,2925,6692,239
30 Sep 1915,6581,1395,6462,276
30 Jun 1915,3541,1185,6402,260
31 Mar 1915,0969385,5972,245
31 Dec 1814,8361,0715,5012,226
30 Sep 1814,5971,9215,1662,157
30 Jun 1814,3642,2185,0652,152
31 Mar 1814,3462,3895,0542,127
31 Dec 1714,5172,5485,0882,107
30 Sep 1714,6991,7875,4542,085
30 Jun 1714,9061,6285,4971,991
31 Mar 1715,0161,5295,4481,975
31 Dec 1615,0241,6295,4321,976
30 Sep 1614,6581,4805,2921,824
30 Jun 1614,0541,3875,1221,798
31 Mar 1613,4691,4185,0001,757
31 Dec 1512,8451,1094,8161,709
30 Sep 1512,3801,2694,6131,738
30 Jun 1512,1801,1544,5151,826
31 Mar 1511,7761,1144,3771,765
31 Dec 1411,3631,1574,2531,704
30 Sep 1411,1061,1584,0601,627
30 Jun 1410,9371,2494,3011,501
31 Mar 1410,9631,2613,9921,480
31 Dec 1311,0951,2023,7051,507

Quality Earnings: MRKC has high quality earnings.

Growing Profit Margin: MRKC's current net profit margins (12.9%) are lower than last year (13.5%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: MRKC's earnings have grown by 13.4% per year over the past 5 years.

Accelerating Growth: MRKC's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: MRKC had negative earnings growth (-6.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (25.4%).

Return on Equity

High ROE: MRKC's Return on Equity (9.5%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 21:23
End of Day Share Price 2024/09/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Merck KGaA is covered by 60 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Martin SchneeAlphaValue
Gerhard SchwarzBaader Helvea Equity Research
Odile RundquistBaader Helvea Equity Research